Completed
A Study to Evaluate the Effect of a Dual CYP2C19 and CYP3A4 Inhibitor, Fluconazole, on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects - FEDR-CP-004
Aggiornato:
17 novembre, 2021
|
ClinicalTrials.gov
Celgene e’ interamente controllata da Bristol-Myers Squibb Company
Sintesi in un linguaggio semplice